{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:06:21Z","timestamp":1791648381747,"version":"4.3.4"},"reference-count":57,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1080\/1744666x.2020.1713754","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T19:05:34Z","timestamp":1578596734000},"page":"119-128","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis"],"prefix":"10.1080","volume":"16","author":[{"given":"Maria","family":"Esposito","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Biotechnological and Applied Clinical Science, University of L\u2019Aquila","place":["L\u2019Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Carubbi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L\u2019Aquila","place":["L\u2019Aquila, Italy"]},{"name":"Department of Medicine, ASL1 Avezzano-Sulmona-L\u2019Aquila","place":["L\u2019Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Giunta","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Alunno","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Perugia","place":["Perugia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L\u2019Aquila","place":["L\u2019Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Biotechnological and Applied Clinical Science, University of L\u2019Aquila","place":["L\u2019Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201706"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.103"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14139"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1627876"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701213"},{"key":"e_1_3_4_10_1","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles KE","year":"2008","unstructured":"Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159:1092\u20131102.","journal-title":"Br J Dermatol"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-0159-1"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1084284"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1329009"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"key":"e_1_3_4_15_1","first-page":"1","article-title":"Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis","volume":"18","author":"Thomas LW","year":"2018","unstructured":"Thomas LW, Lee EB, Wu JJ. Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. J DermatolTreat. 2018;18:1\u20137.","journal-title":"J DermatolTreat"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.59"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.321"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071094"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042915-103905"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122684"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40726"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13354"},{"issue":"3","key":"e_1_3_4_25_1","first-page":"10","article-title":"Current guidelines for psoriasis treatment: a work in progress","volume":"101","author":"Golbari NM","year":"2018","unstructured":"Golbari NM, Porter ML, Kimball AB. Current guidelines for psoriasis treatment: a work in progress. Cutis. 2018;101(3S):10\u201312.","journal-title":"Cutis"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.056"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.10.1133"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20225"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.2.11271"},{"key":"e_1_3_4_30_1","first-page":"535","article-title":"A new generation of high-affinity humanized PEGylated Fab\u2019 fragment anti-tumour necrosis factor-\u03b1 monoclonal antibodies","volume":"3","author":"Weir N","year":"2006","unstructured":"Weir N, Athwal D, Brown D, et al. A new generation of high-affinity humanized PEGylated Fab\u2019 fragment anti-tumour necrosis factor-\u03b1 monoclonal antibodies. Therapy. 2006;3:535\u2013545.","journal-title":"Therapy."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2009.06.009"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211384"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000582"},{"key":"e_1_3_4_35_1","first-page":"S132","article-title":"Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure","volume":"65","author":"Mease PJ","year":"2013","unstructured":"Mease PJ, Wollenhaupt J, Deodhar A, et al. Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure. Arthritis Rheum. 2013;65:S132.","journal-title":"Arthritis Rheum"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000119"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22256"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205198"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10941.x"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.012"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.013"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000942"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15258"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00782-9"},{"key":"e_1_3_4_47_1","first-page":"1","article-title":"Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis","author":"Carubbi F","year":"2019","unstructured":"Carubbi F, Fidanza R, Palmieri M, et al. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. J DermatolTreat. 2019:1\u20136. [Epub ahead of print]","journal-title":"J DermatolTreat"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-015872"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0208-z"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2018.02.010"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120231"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2960-8"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000619"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22848"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2014.967779"},{"issue":"2","key":"e_1_3_4_56_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/annrheumdis-2017-eular.4425","article-title":"THU0381 Certolizumab pegol is effective in uveitis associated to spondyloarthritis refractory to other tumour necrosis factor inhibitors","volume":"76","author":"Hernandez M","year":"2017","unstructured":"Hernandez M, Mesquida M, Llorens V, et al. THU0381 Certolizumab pegol is effective in uveitis associated to spondyloarthritis refractory to other tumour necrosis factor inhibitors. Ann Rheum Dis. 2017; 76(Suppl 2):350.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13170"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2019.04.021"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.057"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2020.1713754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:59:21Z","timestamp":1772711961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2020.1713754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1080\/1744666X.2020.1713754"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2020.1713754","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}